Schonfeld Strategic Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,700	Closed	-$135K	–	2486
2023 Q4	$135K	Hold	5,700	–	–	﹤0.01%	1585
2023 Q3	$115K	Sell	5,700 -24,382	-81%	-$473K	﹤0.01%	1479
2023 Q2	$782K	Sell	30,082 -1,464	-5%	-$41.9K	0.01%	1061
2023 Q1	$656K	Buy	31,546 +2,884	+10%	+$64.6K	0.01%	1090
2022 Q4	$585K	Buy	28,662 +4,630	+19%	+$87.2K	﹤0.01%	1445
2022 Q3	$663K	Buy	24,032 +9,362	+64%	+$269K	0.01%	1547
2022 Q2	$387K	Buy	14,670 +1,426	+11%	+$63.4K	﹤0.01%	1513
2022 Q1	$1.06M	Sell	13,244 -1,380	-9%	-$170K	0.01%	962
2021 Q4	$2.98M	Buy	14,624 +1,083	+8%	+$270K	0.03%	596
2021 Q3	$4.38M	Buy	13,541 +2,623	+24%	+$765K	0.05%	479
2021 Q2	$2.84M	Buy	10,918 +325	+3%	+$99K	0.03%	614
2021 Q1	$4.09M	Buy	10,593 +6,746	+175%	+$2.72M	0.05%	484
2020 Q4	$1.61M	Buy	+3,847	New	+$1.21M	0.02%	660

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's VINC Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2024, closing a stake of 5,700 shares — an estimated $135K sold.

Schonfeld Strategic Advisors first reported a position in VINC in Q4 2020 and held it in 13 quarters. The position peaked at $4.38M in Q3 2021. 40 funds tracked by Wall St. Rank hold VINC as of Q1 2024.

Schonfeld Strategic Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Schonfeld Strategic Advisors sold 5,700 Vincerx Pharma, Inc. Common Stock shares in Q1 2024, an estimated $135K.
Schonfeld Strategic Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
Schonfeld Strategic Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $4.38M in Q3 2021.
40 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.